Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

NCT00610311 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped The study was terminated due to low accrual.

Conditions

Metastatic Melanoma
Skin Cancer

Interventions

DRUG: cyclophosphamide
DRUG: fludarabine phosphate
BIOLOGICAL: Aldesleukin
BIOLOGICAL: ALVAC gp100 Vaccine
BIOLOGICAL: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)

Sponsor

National Cancer Institute (NCI)